Location History:
- Cambridge, GB (2023)
- Lexington, MA (US) (2023)
Company Filing History:
Years Active: 2023
Title: Innovations by Emmanuel Cyrille Pascal Briend in Antibody Development
Introduction
Emmanuel Cyrille Pascal Briend is an accomplished inventor based in Cambridge, GB. He has made significant contributions to the field of biomedicine, particularly through his work on innovative antibody therapies. With three patents to his name, Briend is recognized for his pioneering efforts in developing multispecific molecules that target specific human proteins.
Latest Patents
Briend's most recent patents demonstrate his expertise in antibody technology. One patent focuses on Anti-TIGIT and anti-CD96 antibodies, which provide multispecific molecules that bind specifically to CD96 and TIGIT. This disclosure includes isolated antibodies, pharmaceutical compositions, nucleic acids, expression vectors, and methods for treating subjects with these antibodies. Another notable patent pertains to Anti-CD73 antibodies that antagonize CD73 function and may include additional binding moieties for enhanced activity. This patent also encompasses pharmaceutical compositions, nucleic acids, expression vectors, and treatment methodologies for utilizing these antibodies.
Career Highlights
Briend is currently employed at Agenus Inc., a company known for its dedication to advancing immunotherapy solutions. His work at the company emphasizes the development of innovative therapies aimed at improving patient outcomes in treating various diseases, particularly cancer. His research has placed him at the forefront of therapeutic antibody development.
Collaborations
Throughout his career, Briend has collaborated with talented professionals like Olga Ignatovich and Benjamin Maxime Morin. These partnerships have been instrumental in fostering innovation and driving forward the research and development of new therapeutic approaches.
Conclusion
Emmanuel Cyrille Pascal Briend's inventive contributions in antibody science reflect his commitment to addressing significant medical challenges. His patents, which highlight groundbreaking advancements in multispecific antibody therapies, position him as a key figure in the fight against diseases, particularly in the realm of immunotherapy.